| Literature DB >> 27184782 |
Esther M van der Zwaal1, Barbara A de Weijer2, Elsmarieke M van de Giessen1, Ignace Janssen3, Frits J Berends3, Arnold van de Laar4, Mariette T Ackermans5, Eric Fliers2, Susanne E la Fleur2, Jan Booij1, Mireille J Serlie6.
Abstract
In several studies reduced striatal dopamine D2/3 receptor (D2/3R) availability was reported in obese subjects compared to lean controls. Whether this is a reversible phenomenon remained uncertain. We previously determined the short-term effect of Roux-en-Y gastric bypass surgery (RYGB) on striatal D2/3R availability (using [(123)I]IBZM SPECT) in 20 morbidly obese women. Striatal D2/3R availability was lower compared to controls at baseline, and remained unaltered after 6 weeks, despite significant weight loss. To determine whether long-term bariatric surgery-induced weight loss normalizes striatal D2/3R binding, we repeated striatal D2/3R binding measurements at least 2 years after RYGB in 14 subjects of the original cohort. In addition, we assessed long-term changes in body composition, eating behavior and fasting plasma levels of leptin, ghrelin, insulin and glucose. Mean body mass index declined from 46±7kg/m(2) to 32±6kg/m(2), which was accompanied by a significant increase in striatal D2/3R availability (p=0.031). Striatal D2/3R availability remained significantly reduced compared to the age-matched controls (BMI 22±2kg/m(2); p=0.01). Changes in striatal D2/3R availability did not correlate with changes in body weight/fat, insulin sensitivity, ghrelin or leptin levels. Scores on eating behavior questionnaires improved and changes in the General Food Craving Questionnaire-State showed a borderline significant correlation with changes in striatal D2/3R availability. These findings show that striatal D2/3R availability increases after long-term bariatric-surgery induced weight loss, suggesting that reduced D2/3R availability in obesity is a reversible phenomenon.Entities:
Keywords: Dopamine D(2) receptors; Eating behavior; Insulin sensitivity; Obesity; Weight loss
Mesh:
Substances:
Year: 2016 PMID: 27184782 DOI: 10.1016/j.euroneuro.2016.04.009
Source DB: PubMed Journal: Eur Neuropsychopharmacol ISSN: 0924-977X Impact factor: 4.600